Background Bronchodilators are the mainstay of pharmacological treatment in chronic
obstructive pulmonary disease (COPD), and long-acting muscarinic antagonist (LAMA) …

Currently available inhaled bronchodilators used as therapy for chronic obstructive
pulmonary disease (COPD) necessitate multiple daily dosing. The present study evaluates …

Abstract Abstract Tiotropium bromide (Spiriva®) is a long-acting anticholinergic
bronchodilator that maintains bronchodilation for at least 24 hours, allowing once-daily …

Background: Current guidelines recommend the use of inhaled tiotropium in patients with
stable chronic obstructive pulmonary disease (COPD). However, this statement is based on …

Tiotropium bromide is a long-acting, once-daily inhaled anticholinergic approved for the
treatment of chronic obstructive pulmonary disease (COPD). Functional and kinetic …

Background Tiotropium is a long-acting inhaled anticholinergic developed for the treatment
of chronic obstructive pulmonary disease (COPD) and has been available since 2002. We …

Background Previous studies showing that tiotropium improves multiple end points in
patients with chronic obstructive pulmonary disease (COPD) led us to examine the long-term …

Background: In chronic obstructive pulmonary disease (COPD), inhaled tiotropium bromide,
a long-acting anticholinergic, has been shown to exert a sustained bronchodilator effect and …

BACKGROUND:: Tiotropium bromide is a new inhaled anticholinergic agent approved for
once-daily, long-term maintenance treatment of bronchospasm associated with chronic …

Tiotropium, a novel once-daily inhaled anticholinergic, has been shown to improve lung
function over a 24-h period. In order to extend these findings, health-outcomes were …